A phase 2 study of XL999 administered intravenously to subjects with acute myeloid leukemia
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2015
At a glance
- Drugs XL 999 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Symphony Evolution
- 23 Feb 2010 Actual number of patients (14) added as reported by ClinicalTrials.gov record.
- 27 Jun 2007 Status changed from suspended to discontinued.
- 06 Nov 2006 Status change